依那普利联合厄贝沙坦对糖尿病合并高血压患者的有效性及对血管内皮功能的影响

摘要/Abstract

摘要： 目的：观察分析依那普利联合厄贝沙坦治疗对糖尿病合并高血压患者的有效性及对患者血管内皮功能的影响。方法：回顾性分析2017年6月至2019年7月间我院收治的142例糖尿病合并高血压患者的临床资料，依据治疗措施的不同进行分组，其中71例接受依那普利联合厄贝沙坦治疗者作治疗组，71例接受厄贝沙坦治疗者作对照组，比较两组患者血糖指标、血压及血管内皮功能指标的水平，记录两组患者的不良反应发生情况。结果：治疗后，治疗组患者的餐后2 h血糖(2hPBG)、空腹血糖(FPG)及糖化血红蛋白(HbA1c)水平均比对照组更低(P<0.05)。治疗组患者治疗后的收缩压(SBP)为(123.28±5.34)mmHg，舒张压(DBP)为(81.32±3.19)mmHg，分别低于对照组的(132.47±6.46)mmHg与(92.83±4.58)mmHg(P<0.05)。治疗后，治疗组患者的血管内皮功能指标血管内皮生长因子(VEGF)、一氧化氮(NO)水平及NO/ET-1比值均高于对照组（P<0.05），内皮素-1(ET-1)水平低于对照组(P<0.05)。治疗期间，治疗组患者不良反应的发生率(8.45%)高于对照组患者(5.63%)，但差异无统计学意义(P>0.05)。结论：依那普利联合厄贝沙坦治疗2型糖尿病(T2DM)合并原发性高血压患者能有效促进NO与ET-1浓度的平衡，增加VEGF、NO/ET-1比值的表达，对改善血管内皮细胞功能，维持血管舒缩功能平衡有积极意义，同时联合用药治疗不会增加不良反应发生率，安全性较好。

关键词: font-size:medium, ">依那普利；厄贝沙坦；糖尿病；高血压；有效性；血管内皮功能

Abstract: Objective：To observe and analyze the efficacy of enalapril combined with irbesartan in diabetes patients with hypertension and its effects on vascular endothelial function. Methods：The clinical data of 142 cases of diabetic patients with hypertension admitted in our hospital from June 2017 to July 2019 were retrospectivly analized. According to different treatment measures， 71 patients received enalapril combined with irbesartan treatment were set as the treatment group， and 71 patients received irbesartan treatment were set as the control group. The levels of blood glucose indexes， blood pressure and vascular endothelial function indicators were compared between the two groups of patients before and after treatment. At the same time， the occurrence of adverse reactions in both groups was recorded. Results：After treatment， the levels of 2hPBG， FPG and HbA1c of patients in the treatment group were lower than those in the control group (P<0.05). After treatment， the SBP of patients in the treatment group was (123.28±5.34) mmHg， and the DBP was (81.32±3.19) mmHg， which were lower than (132.47±6.46) mmHg and (92.83±4.58) mmHg in the control group(P<0.05). After treatment， the levels of vascular endothelial function indicators VEGF，NO and NO/ET-1 of patients in the treatment group were higher than those in the control group(P<0.05)， and the levels of ET-1 was lower than that in the control group (P<0.05). The incidence of adverse reactions during treatment in the treatment group (8.45%) was higher than that in the control group (5.63%)， but the difference was not statistically significant (P>0.05). Conclusion：Enalapril combined with irbesartan in the treatment of T2DM patients with essential hypertension can effectively promote the balance of NO and ET-1 concentration， increase the expression of VEGF， NO/ET-1 ratio， improve the function of vascular endothelial cells， maintain the balance of vasomotor function， and the combined treatment does not increase the incidence of adverse reactions and has good safety.

Key words: font-size:medium, ">Enalapril； Irbesartan； Diabetes； Hypertension； Effectiveness； Vascular endothelial function

中图分类号:

赵旭敏, 刘霞, 王艺臻. 依那普利联合厄贝沙坦对糖尿病合并高血压患者的有效性及对血管内皮功能的影响[J]. 中国医药导刊, 2022, 24(12): 1199-1203.

ZHAO Xumin, LIU Xia, WANG Yizhen. The Efficacy of Enalapril Combined with Irbesartan in Diabetic Patients with Hypertension and Its Effects on Vascular Endothelial Function[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(12): 1199-1203.

参考文献

[1]蒲静，王秋林，王沛坚，等. 坎地沙坦与厄贝沙坦联合二甲双胍治疗非糖尿病肥胖型高血压患者临床疗效及对血管内皮功能影响的多中心联合随机对照研究[J]. 实用心脑肺血管病杂志，2018， 26(11)：40-44，49.
     [2]杜蓥漩，王慧. 西格列汀对糖尿病合并高血压患者血压，动脉僵硬度和内皮功能的影响[J]. 广西医学，2020，42(10)：1193-1197.
     [3]马盼，庞雪峰. 厄贝沙坦联合羟苯磺酸钙对早期2型糖尿病合并高血压患者肾内血流动力学的影响[J]. 海南医学，2018，29(8)：1055-1059.
     [4]永佳，王丹阳，永雪薇. 马来酸依那普利叶酸片在H型高血压合并糖尿病的老年病人中的疗效研究[J]. 实用老年医学，2019，33(11)：1085-1088.
     [5]中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版) [J]. 中国实用内科杂志，2018，38(4)：292-344.
     [6]中国高血压防治指南修订委员会，高血压联盟(中国)，中华医学会心血管病学分会，等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志，2019，24(1)：24-56.
     [7]胡蓓.药物临床试验质量管理规范(GCP)[C].全国儿童新药临床试验学术研讨会.2012.
     [8]Griffin T， Dinneen S. In T2DM， weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia[J]. Ann Intern Med，2021，174(3)：JC34.
     [9]王哲辉，杨土保. 独立与联合时糖尿病及高血压的心脑血管并发症风险差异[J]. 中国卫生统计，2021，38(1)：18-24.
     [10]奚艳，唐海沁，蒋品，等. 厄贝沙坦联合氨氯地平对糖尿病高血压合并高尿酸血症患者降压及降尿酸疗效的Meta分析[J]. 中国临床保健杂志，2018，36(1)：36-39.
     [11]吴冠吉，李春花，张涛，等. 厄贝沙坦对糖尿病合并高血压患者血清脂联素水平影响研究[J]. 陕西医学杂志，2018，47(8)：106-108.
     [12]郭杨燕，孙行云，孟繁兴，等. 血塞通注射液对OGD/R损伤小鼠脑微血管内皮细胞VEGF通路表达的影响及机制研究[J]. 中国医药导报，2021，18(26)：12-16.
     [13]Bikos A， Loutradis C， Angeloudi E， et al. The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension： a randomized cross-over study[J]. J Hypertens， 2019， 37(2)：432-442.
     [14]杨张娅，温恩懿. 内皮素-1在血管平滑肌细胞增殖作用中的研究进展[J]. 心血管病学进展，2020，41(5)：524-526，530.
     [15]赵小辉，卢双动，陈杰，等. 血浆尿酸、心房利尿钠肽、内皮素-1水平对急性ST段抬高型心肌梗死并发房颤的预测研究[J]. 中国医药导报，2022，19(11)：73-76.

快速检索引用检索图表检索高级检索